AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour analyses
Number of subjects: 1302
Study 38951008 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis of indeterminate potential
Number of subjects: 1302
Study 38951012 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBM) applied to bilateral knees and lumbar paraspinal points.
Number of subjects: 0
Study 38951012 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (not explicitly detailed in the abstract).
Number of subjects: 0
Study 38951253 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention for 12 weeks
Number of subjects: 60
Study 38951253 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention including SC tasks
Number of subjects: 60
Study 38951253 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 38951256 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatGPT
Number of subjects: 200
Study 38951314 — intervention group
Group type: EXPERIMENTAL
Intervention: TG-LASIK
Number of subjects: 34
Study 38951314 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 34
Study 38951507 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMS
Number of subjects: 446
Study 38951507 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50
Number of subjects: 446
Study 38951507 — intervention group
Group type: EXPERIMENTAL
Intervention: Different IBCMS methods
Number of subjects: 446
Study 38951532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile behavior change program for weight loss
Number of subjects: 0
Study 38951699 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integration of specialised palliative care (SPC) alongside tumour-specific palliative treatment
Number of subjects: 118
Study 38951699 — intervention group
Group type: COMPARATOR
Intervention: Tumour-specific treatment alone (Control)
Number of subjects: 118
Study 38951777 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-ART intervention (six weekly sessions of 60 to 90 minutes)
Number of subjects: 200
Study 38951777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 38951803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 32
Study 38951803 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 32
Study 38951803 — intervention group
Group type: COMPARATOR
Intervention: Aerobic and resistance exercise
Number of subjects: 32
Study 38951815 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy measurement
Number of subjects: 0
Study 38951815 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up every 2 years via telephone call
Number of subjects: 0
Study 38951853 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-emtansine (T-DM1)
Number of subjects: 37
Study 38951902 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD oral solution
Number of subjects: 468
Study 38951902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 38951929 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVERY trial participants
Number of subjects: 38510
Study 38951929 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 38510
Study 38951940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic toric IOL Clareon CNW0T3-9
Number of subjects: 130
Study 38952054 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib plus obinutuzumab
Number of subjects: 10
Study 38952209 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme
Number of subjects: 73
Study 38952498 — intervention group
Group type: COMPARATOR
Intervention: Lumbar stability exercise (LSE) group
Number of subjects: 80
Study 38952498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stability exercise with teeth clenching (LSETC) group
Number of subjects: 80
Study 38952513 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing patients with video about intensive care before cardiac surgery
Number of subjects: 90
Study 38952513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video information)
Number of subjects: 90
Study 38952554 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (oral, maximum daily dose of 160 mg for weeks 1-3 of each 4-week cycle)
Number of subjects: 143
Study 38952672 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB)
Number of subjects: 38
Study 38952731 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 disease
Number of subjects: 0
Study 38952731 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services utilization
Number of subjects: 0
Study 38952731 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study
Number of subjects: 0
Study 38952780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 0
Study 38952884 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (2 doses of 12mg intramuscular)
Number of subjects: 146
Study 38952884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 doses of 12mg intramuscular)
Number of subjects: 146
Study 38952884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 doses)
Number of subjects: 146
Study 38953034 — intervention group
Group type: EXPERIMENTAL
Intervention: Icanbelimod 0.5 mg
Number of subjects: 36
Study 38953034 — intervention group
Group type: EXPERIMENTAL
Intervention: Icanbelimod (various doses)
Number of subjects: 36
Study 38953034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 38953152 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 7
Study 38953152 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy participants)
Number of subjects: 7
Study 38953334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 40
Study 38953334 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 40
Study 38953542 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adalimumab induction dose
Number of subjects: 0
Study 38953542 — intervention group
Group type: COMPARATOR
Intervention: Standard adalimumab dosing regimen
Number of subjects: 0
Study 38953600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adalimumab induction regimen
Number of subjects: 0
Study 38953600 — intervention group
Group type: COMPARATOR
Intervention: Standard adalimumab dosing regimen
Number of subjects: 0
Study 38953850 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 (100, 200, or 400 μg) plus BCG (50 mg)
Number of subjects: 91
Study 38953850 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 (400 μg) plus BCG (50 mg)
Number of subjects: 91
Study 38953850 — intervention group
Group type: COMPARATOR
Intervention: N-803 (400 μg) alone
Number of subjects: 91
Study 38953850 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 plus BCG
Number of subjects: 91
Study 38953855 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus bevacizumab
Number of subjects: 0
Study 38953855 — intervention group
Group type: COMPARATOR
Intervention: Trifluridine/tipiracil alone
Number of subjects: 0
Study 38953934 — intervention group
Group type: EXPERIMENTAL
Intervention: High FDG Ki group (n=8, Ki > 2.779 ml/min/100 g)
Number of subjects: 15
Study 38953934 — intervention group
Group type: COMPARATOR
Intervention: Low FDG Ki group (n=7, Ki ≤ 2.779 ml/min/100 g)
Number of subjects: 15
Study 38953934 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in Ki > 73.1%
Number of subjects: 15
Study 38953934 — intervention group
Group type: EXPERIMENTAL
Intervention: High FDG Ki group after hypo-CCRT
Number of subjects: 15
Study 38953936 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based cervical stabilization exercises, performed three times a week for six weeks in addition to routine medication.
Number of subjects: 26
Study 38953936 — intervention group
Group type: COMPARATOR
Intervention: Control group continued routine medication only.
Number of subjects: 26
Study 38953938 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable stent (BES)
Number of subjects: 201
Study 38953938 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable stent (SES)
Number of subjects: 201
Study 38954010 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1) (Arm A)
Number of subjects: 13
Study 38954010 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm B)
Number of subjects: 13
Study 38954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in the elderly prediction score (TERPS)
Number of subjects: 218
Study 38954035 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and radiological parameters used to calculate TERPS
Number of subjects: 218
Study 38954035 — intervention group
Group type: EXPERIMENTAL
Intervention: TERPS risk prediction score
Number of subjects: 218
Study 38954131 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral catheterization (TUC)
Number of subjects: 240
Study 38954131 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheterization (SPC)
Number of subjects: 240
Study 38954149 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support intervention delivered by the interprofessional ICU team
Number of subjects: 0
Study 38954149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38954176 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 0
Study 38954217 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop spinal cord stimulation (CL-SCS)
Number of subjects: 135
Study 38954226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg SC at baseline, weeks 1 and 2, and every 2 weeks thereafter until week 16
Number of subjects: 126
Study 38954226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg SC
Number of subjects: 126
Study 38954226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 38954317 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-46000 once monthly (q1m)
Number of subjects: 336
Study 38954317 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-46000 once every 2 months (q2m)
Number of subjects: 336
Study 38954317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from RISE)
Number of subjects: 336
Study 38954402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 147
Study 38954402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 38954415 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus abstinence-contingent financial incentives (UC plus FI)
Number of subjects: 320
Study 38954415 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 320
Study 38954433 — intervention group
Group type: EXPERIMENTAL
Intervention: UV4.me [basic]
Number of subjects: 1369
Study 38954433 — intervention group
Group type: EXPERIMENTAL
Intervention: UV4.me2 [enhanced]
Number of subjects: 1369
Study 38954433 — intervention group
Group type: COMPARATOR
Intervention: e-pamphlet
Number of subjects: 1369
Study 38954475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (30 sessions over 10 weeks)
Number of subjects: 85
Study 38954475 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback therapy (3 sessions over 10 weeks)
Number of subjects: 85
Study 38954482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting Self-Management of Healthy Behaviors intervention
Number of subjects: 0
Study 38954482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38954674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Brief Intervention (nurse-led, 20 minutes emotional and educational support discussion with a leaflet)
Number of subjects: 40
Study 38954674 — intervention group
Group type: COMPARATOR
Intervention: Standard care information (Control group)
Number of subjects: 40
Study 38954680 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (Myfembree®) after surgical myomectomy
Number of subjects: 136
Study 38954680 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) after surgical myomectomy
Number of subjects: 136
Study 38954692 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 52
Study 38954692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Number of subjects: 52
Study 38954692 — intervention group
Group type: COMPARATOR
Intervention: Probiotic capsule (Lactobacillus salivarius WB21, 6.7 x 108 CFU, xylitol 280mg, 3 times a day for 14 days)
Number of subjects: 52
Study 38954692 — intervention group
Group type: COMPARATOR
Intervention: Control appointments
Number of subjects: 52
Study 38954699 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition assessed with the NEPSY II test
Number of subjects: 40
Study 38954699 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional markers assessed with the Differential Emotion Scale IV and the Revised Beliefs About Voices Questionnaire
Number of subjects: 40
Study 38954699 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognition and emotional markers
Number of subjects: 40
Study 38954701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm with free first-line ACT for positive mRDT and PMRs receiving USD $0.2 for every mRDT performed
Number of subjects: 48
Study 38954701 — intervention group
Group type: COMPARATOR
Intervention: Control arm offering subsidized mRDT testing for USD $0.66
Number of subjects: 48
Study 38954782 — intervention group
Group type: EXPERIMENTAL
Intervention: TK216 administered as a 14-day continuous infusion
Number of subjects: 85
Study 38954782 — intervention group
Group type: EXPERIMENTAL
Intervention: TK216 plus vincristine (added on day 1 after cycle 2, per investigators' choice)
Number of subjects: 85
Study 38954785 — intervention group
Group type: EXPERIMENTAL
Intervention: CaboNivo
Number of subjects: 120
Study 38954785 — intervention group
Group type: EXPERIMENTAL
Intervention: CaboNivoIpi
Number of subjects: 120
Study 38954834 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic deletion of JAM-C (Junctional Adhesion Molecule-C) in leukemic stem cells (LSCs)
Number of subjects: 0
Study 38954834 — intervention group
Group type: EXPERIMENTAL
Intervention: AP-1/TNF-α gene signature
Number of subjects: 0
Study 38954834 — intervention group
Group type: EXPERIMENTAL
Intervention: LSC-17 score
Number of subjects: 0
Study 38954844 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial prophylactic exchange blood transfusion (SPEBT); 12 patients received at least 1 SPEBT, 11 received ≥3.
Number of subjects: 35
Study 38954844 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control); 16 control participants required at least 1 transfusion.
Number of subjects: 35
Study 38954860 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan (GM) analysis in exhaled breath condensate (EBC)
Number of subjects: 75
Study 38954860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiling (IL-6 and TNF-α)
Number of subjects: 75
Study 38954860 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage fluid (BALF) GM levels
Number of subjects: 75
Study 38954874 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (NS)
Number of subjects: 676
Study 38954874 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine extended release (XR)
Number of subjects: 676
Study 38954899 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, gemcitabine, and oxaliplatin (first-line treatment)
Number of subjects: 67
Study 38954929 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-Walk intervention (motivational enhancement therapy with 3 counseling sessions, Fitbit Charge 2, exercise diaries, telephone follow-up, motivational emails, optional walking groups)
Number of subjects: 60
Study 38954929 — intervention group
Group type: COMPARATOR
Intervention: Control group (PA education alone)
Number of subjects: 60
Study 38955178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 1,200 mg/day (n=3)
Number of subjects: 20
Study 38955178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 2,400 mg/day (n=6)
Number of subjects: 20
Study 38955178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 3,600 mg/day (n=3)
Number of subjects: 20
Study 38955178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 6,000 mg/day (n=2)
Number of subjects: 20
Study 38955178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terameprocol at 6,000 mg/day in fed state (n=4)
Number of subjects: 20
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gut microbiota in 1st trimester with excessive GWG
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota trajectory across gestations
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota composition in relation to GWG
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Richness index of alpha diversity
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Evenness index in 2nd trimester
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxonomic differences in 1st trimester
Number of subjects: 110
Study 38955351 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxonomic differences in 2nd and 3rd trimesters
Number of subjects: 110
Study 38955352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligilactobacillus salivarius V4II-90 at 1 × 10^9 cfu/day for 12 weeks
Number of subjects: 40
Study 38955352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38955368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 844
Study 38955368 — intervention group
Group type: COMPARATOR
Intervention: Plasma solution
Number of subjects: 844
Study 38955437 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated supine position with back support
Number of subjects: 104
Study 38955437 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 104
Study 38955554 — intervention group
Group type: EXPERIMENTAL
Intervention: High Troponin I (TnI > 6 ng/L)
Number of subjects: 1615
Study 38955554 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP > 2 mg/L)
Number of subjects: 1615
Study 38955577 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (n = 37)
Number of subjects: 104
Study 38955577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 104
Study 38955669 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to local SSSs, brief advice, and e-cigarette starter kit (n=505)
Number of subjects: 1007
Study 38955669 — intervention group
Group type: COMPARATOR
Intervention: Signposting to SSSs (contact details provided) (n=502)
Number of subjects: 1007
Study 38955669 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to SSSs (n=505)
Number of subjects: 1007
Study 38955669 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with 24 intervention participants
Number of subjects: 1007
Study 38955811 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational physical activity (OPA) under high work-related stress
Number of subjects: 19
Study 38955811 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-time moderate and vigorous physical activity
Number of subjects: 19
Study 38955921 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP composite endpoint
Number of subjects: 0
Study 38955921 — intervention group
Group type: EXPERIMENTAL
Intervention: PASDAS
Number of subjects: 0
Study 38955921 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 0
Study 38955966 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 463
Study 38955966 — intervention group
Group type: COMPARATOR
Intervention: MCV4-TT
Number of subjects: 463
Study 38955966 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT/9vHPV/Tdap-IPV
Number of subjects: 463
Study 38956196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (D + Q)
Number of subjects: 60
Study 38956196 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 38956196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (D + Q) in high senescent cell burden women
Number of subjects: 60
Study 38956317 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with PerioRisk information (RISK group)
Number of subjects: 0
Study 38956317 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) without PerioRisk information (CTR group)
Number of subjects: 0
Study 38956498 — intervention group
Group type: EXPERIMENTAL
Intervention: Team training programme
Number of subjects: 0
Study 38956498 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBAR communication tool
Number of subjects: 0
Study 38956510 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer2Me intervention (mentorship by AYA survivor for 3 months)
Number of subjects: 180
Study 38956510 — intervention group
Group type: COMPARATOR
Intervention: Single AYA-specific consultation (control condition)
Number of subjects: 180
Study 38956517 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated participants
Number of subjects: 861
Study 38956517 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvaccinated participants from Allada with at least one previous morbidity
Number of subjects: 861
Study 38956517 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination coverage
Number of subjects: 861
Study 38956562 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video followed by self-study (Vid-Self) in Study 1 (n=42)
Number of subjects: 138
Study 38956562 — intervention group
Group type: COMPARATOR
Intervention: Self-study followed by instructional video (Self-Vid) in Study 1 (n=36)
Number of subjects: 138
Study 38956562 — intervention group
Group type: COMPARATOR
Intervention: Self-Vid after seven days (Study 1)
Number of subjects: 138